Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | F13A1 | P00488 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | TGM1 | P22735 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27556840 | 0.93 | ESR2 (0.41) | ESR2NR1H2ADORA1USP2SMN1; SMN2 | |
| SCHEMBL27557006 | 0.79 | ADORA1 (0.46) | ESR2NR1H2HPGDADORA1USP2 | |
| SCHEMBL2817602 | 0.78 | ESR2 (0.43) | ESR2NR1H2MEN1KMT2AMAPK1 | |
| SCHEMBL994232 | 0.78 | ESR2 (0.43) | ESR2NR1H2MEN1KMT2AMAPK1 | |
| SCHEMBL30800944 | 0.77 | ESR2 (0.45) | ESR2NR1H2HPGDMEN1KMT2A | |
| SCHEMBL16075641 | 0.77 | ESR2 (0.45) | ESR2NR1H2HPGDMEN1KMT2A | |
| SCHEMBL19341961 | 0.77 | ESR2 (0.45) | ESR2NR1H2HPGDMEN1KMT2A | |
| SCHEMBL7884848 | 0.73 | KMT2A (0.48) | ESR2NR1H2HPGDMEN1KMT2A | |
| SCHEMBL4938455 | 0.72 | HSD17B10 (0.34) | SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL4938451 | 0.72 | HSD17B10 (0.34) | SMN1; SMN2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638529-B2 | anti-bacterial agents; staphylococci; coliform bacteria; 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide; bridged bicyclic ureas or carbamates having bridgehead nitrogen | AVENTIS PHARMA S.A. (FR) | 2009-12-29 | — | — | US | disclosed |
| US-20060046995-A1 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046995-A1 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, SDHB, SDHA | ESR2 4411/4885NR1H2 3149/4885HPGD 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.